The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
The outbreak led to urgent action by medical experts across the world to combat this devastating disease; including the setting up of trials of vaccines to stop the disease taking hold.
This global commitment to develop a vaccine against the disease suggested eight options, out of a starting pool of 15 candidates, should be evaluated in clinical trials worldwide by the end of 2015.
Professor Sanjeev Krishna, of St George’s University of London’s Institute for Infection and Immunity, said: “An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis. The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively.
“We need a system of specialists, medical experts and organisers that maintains vigilance against outbreak diseases like Ebola.
“We should continue to improve ways to make, evaluate and deliver vaccines when they are needed, often in parts of the world lacking in infrastructure for diagnosing infections and providing treatments.”
He explained that considering the persistent replication of the vaccine which is called rVSV-?GP-ZEBOV in children and adolescents, further studies investigating lower doses in this population are warranted.
The vaccine contains a non-infectious portion of a gene from the Zaire Ebola virus. The St George’s researchers worked with colleagues on a vaccine trial in Gabon.
In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebolavirus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebolavirus outbreaks in the past.
The vaccine was one of two being examined as a ‘candidate’ option by the World Health Organisation to identify urgently a vaccine to combat the Ebola virus outbreak in West Africa.
The clinical trial was led by colleagues at University of Tübingen in Germany, coordinated by Professor Peter Kremsner with their partner institute CERMEL in Lambaréné, Gabon.
Learn more: Ebola vaccine tested in adults and children in Africa hailed a success
The Latest on: Ebola vaccine
[google_news title=”” keyword=”Ebola vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Africa: Vaccines save 51.2m lives in 50 yearson April 27, 2024 at 12:10 am
AN estimated 51.2 million lives have been saved through vaccines in the African region over the past 50 years. For every infant life saved over that period, close to 60 years of life are lived, a new ...
- Soligenix extends patent protection for its Filovirus vaccine to United Kingdom and South Africaon April 26, 2024 at 10:30 pm
Soligenix extends patent protection for its Filovirus vaccine to United Kingdom and South Africa: Princeton, New Jersey Saturday, April 27, 2024, 11:00 Hrs [IST] Soligenix, Inc, a ...
- Improving public health communication in African epidemics: Lessons learned and future directionson April 26, 2024 at 10:20 am
Zika and other public health emergencies, effective communication of public health messages is crucial to control the spread of disease, maintain public trust, and encourage compliance with health ...
- 154 million lives saved: Landmark study highlights power of vaccinationon April 25, 2024 at 11:23 am
including the HPV vaccine and vaccines for outbreaks of measles, cholera, yellow fever, Ebola and meningitis. "Gavi was established to build on the partnership and progress made possible by EPI, ...
- Global immunization efforts saved 154 million lives over past 50 years: The Lanceton April 25, 2024 at 12:21 am
Of the vaccines included in the study, the measles vaccination had the most significant impact on reducing infant mortality, accounting for 60 per cent of the lives saved due to immunization.
- Global Immunization Efforts Have Saved At Least 154 Million Lives Over the Past 50 Years [press release]on April 24, 2024 at 11:10 pm
A major landmark study just published by The Lancet reveals that global immunization efforts have saved an estimated 154 million lives - or the equivalent of 6 lives every minute of every year - over ...
- Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africaon April 24, 2024 at 9:30 pm
About SuVax™ SuVax™ is a subunit protein vaccine of recombinantly expressed Sudan Ebola virus glycoprotein, developed in partnership with Dr. Axel Lehrer at the University of Hawaiʽi at Mānoa. The ...
- Global Immunization Efforts: At least 154 million lives saved over past 50 yearson April 24, 2024 at 8:10 am
A major landmark study by The Lancet reveals that global immunization efforts have saved an estimated 154 million lives - or the equivalent of 6 lives every minute of every year - over the past 50 ...
- Believed to be the source of Ebola, this Kenya cave could be ground zero for the next pandemicon April 22, 2024 at 6:54 pm
Located in Kenya's Mount Elgon National Park, the Kitum Cave was reportedly the origin point for the Ebola and Marburg viruses, of which the latter has been termed as 'epidemic-prone' by the World ...
- Ebola And Marburg Viruson April 22, 2024 at 9:56 am
Find Ebola And Marburg Virus Latest News, Videos & Pictures on Ebola And Marburg Virus and see latest updates, news, information from NDTV.COM. Explore more on Ebola And Marburg Virus.
via Google News and Bing News